At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of probable Alzheimer's disease
- ✓Has reliable and available caregiver to assist with medication and appointments
- ✓On a stable dose of cholinesterase inhibitor, or not planning to re-initiate cholinergic therapies during the study
- ✕Current or recent use (<6 months) of menopausal Hormone Replacement Therapy (HRT)
- ✕Current or recent use (<4 months) of oral antibiotic therapy
- ✕Typical dietary intake of soy isoflavones >5 mg/day
- ✕History of significant gastrointestinal or colon disease, or colon/intestinal resection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alzheimer's Disease: Potential Benefit of Isoflavones
In Brief
A Phase 2 clinical trial evaluating Novasoy and Placebo for Alzheimer's Disease. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to evaluate the potential effects of soy isoflavone supplements on cognitive function for men and women with Alzheimer's Disease (AD). Preliminary studies evaluating the effects of soy supplements on memory in cognitively healthy older adults have yielded promising results that are now being evaluated in patients with AD. It is hypothesized that isoflavone supplements will ameliorate cognitive declines for older adults diagnosed with Alzheimer's disease, when compared to subjects on placebo.
Study Details
Timeline
Interventions
100mg/day soy isoflavones
100mg/day matching placebo